Q3 Earnings Forecast for TSE:MDP Issued By Raymond James

Medexus Pharmaceuticals Inc. (TSE:MDP) – Investment analysts at Raymond James lowered their Q3 2026 earnings per share estimates for Medexus Pharmaceuticals in a note issued to investors on Tuesday, January 7th. Raymond James analyst M. Freeman now anticipates that the company will post earnings per share of $0.22 for the quarter, down from their prior forecast of $0.24. Raymond James currently has a “Strong-Buy” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.

Other equities research analysts also recently issued research reports about the stock. Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Two analysts have rated the stock with a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, Medexus Pharmaceuticals presently has a consensus rating of “Strong Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Stock Performance

Shares of MDP stock opened at C$4.04 on Thursday. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$4.24. The company’s 50 day moving average price is C$2.77 and its two-hundred day moving average price is C$2.53. The company has a market capitalization of C$99.10 million, a P/E ratio of 80.80 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.